Copper Rock Capital Partners Lifted Zoetis (ZTS) Position By $4.95 Million; Tetraphase Pharmaceuticals (TTPH) Shorts Up By 4.15%

February 1, 2018 - By Martha Paddon

Tetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH) had an increase of 4.15% in short interest. TTPH’s SI was 3.27M shares in February as released by FINRA. Its up 4.15% from 3.14 million shares previously. With 410,200 avg volume, 8 days are for Tetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH)’s short sellers to cover TTPH’s short positions. The SI to Tetraphase Pharmaceuticals Incorporated’s float is 8.88%. The stock decreased 4.26% or $0.26 during the last trading session, reaching $5.84. About 459,370 shares traded. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has risen 106.58% since February 1, 2017 and is uptrending. It has outperformed by 89.88% the S&P500.

Copper Rock Capital Partners Llc increased Zoetis Inc (ZTS) stake by 1238% reported in 2017Q3 SEC filing. Copper Rock Capital Partners Llc acquired 78,514 shares as Zoetis Inc (ZTS)’s stock rose 14.85%. The Copper Rock Capital Partners Llc holds 84,856 shares with $5.37M value, up from 6,342 last quarter. Zoetis Inc now has $37.39 billion valuation. The stock decreased 2.07% or $1.62 during the last trading session, reaching $76.73. About 4.14 million shares traded or 69.62% up from the average. Zoetis Inc. (NYSE:ZTS) has risen 29.89% since February 1, 2017 and is uptrending. It has outperformed by 13.19% the S&P500.

Since August 17, 2017, it had 0 buys, and 4 sales for $245,860 activity. Dumas Jacques sold $41,928 worth of stock.

Among 13 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 5 have Buy rating, 0 Sell and 8 Hold. Therefore 38% are positive. Tetraphase Pharmaceuticals has $57 highest and $8 lowest target. $24.13’s average target is 313.18% above currents $5.84 stock price. Tetraphase Pharmaceuticals had 25 analyst reports since August 6, 2015 according to SRatingsIntel. Stifel Nicolaus upgraded the stock to “Buy” rating in Wednesday, July 26 report. The firm has “Buy” rating given on Thursday, November 19 by SunTrust. The rating was downgraded by Needham to “Hold” on Wednesday, September 9. On Wednesday, September 9 the stock rating was downgraded by Cantor Fitzgerald to “Hold”. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, August 6. Robert W. Baird downgraded it to “Neutral” rating and $10 target in Wednesday, September 9 report. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Neutral” rating by Nomura on Wednesday, September 9. The firm has “Neutral” rating by SunTrust given on Wednesday, September 9. As per Wednesday, September 9, the company rating was downgraded by Stifel Nicolaus. The firm has “Outperform” rating by BMO Capital Markets given on Thursday, October 5.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $300.26 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It currently has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

Investors sentiment increased to 2.21 in Q3 2017. Its up 0.90, from 1.31 in 2017Q2. It improved, as 10 investors sold Tetraphase Pharmaceuticals, Inc. shares while 14 reduced holdings. 19 funds opened positions while 34 raised stakes. 29.38 million shares or 42.90% more from 20.56 million shares in 2017Q2 were reported. Tekla Lc has 859,322 shares. Invesco holds 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) for 51,639 shares. Eventide Asset Mgmt Ltd holds 0.18% or 463,700 shares. 760 were reported by Mufg Americas Holdg. Ameriprise Finance holds 22,500 shares. Legal And General Grp Pcl, United Kingdom-based fund reported 14,360 shares. 2.08M are owned by Millennium Ltd Liability Com. Northern has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Cubist Systematic Strategies Ltd Com holds 0.01% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) or 28,546 shares. Wade G W & reported 15,000 shares stake. Commercial Bank Of Montreal Can stated it has 718 shares. Renaissance Tech Ltd Liability Corp has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). California Pub Employees Retirement Systems owns 242,200 shares. Aqr Management Limited Liability invested 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Brighton Jones Lc invested 0.01% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH).

Among 21 analysts covering Zoetis Inc (NYSE:ZTS), 16 have Buy rating, 0 Sell and 5 Hold. Therefore 76% are positive. Zoetis Inc has $89.0 highest and $48 lowest target. $70.76’s average target is -7.78% below currents $76.73 stock price. Zoetis Inc had 69 analyst reports since July 24, 2015 according to SRatingsIntel. Cowen & Co upgraded it to “Outperform” rating and $60 target in Thursday, December 15 report. The company was maintained on Wednesday, October 25 by BMO Capital Markets. The stock of Zoetis Inc. (NYSE:ZTS) has “Buy” rating given on Tuesday, June 20 by Hilliard Lyons. The stock of Zoetis Inc. (NYSE:ZTS) earned “Buy” rating by Cowen & Co on Thursday, August 24. The firm has “Buy” rating given on Friday, June 16 by Jefferies. On Thursday, January 4 the stock rating was upgraded by Citigroup to “Buy”. BMO Capital Markets downgraded Zoetis Inc. (NYSE:ZTS) on Tuesday, June 13 to “Market Perform” rating. The stock of Zoetis Inc. (NYSE:ZTS) earned “Overweight” rating by Piper Jaffray on Thursday, December 15. BMO Capital Markets maintained it with “Buy” rating and $60 target in Friday, May 5 report. The stock of Zoetis Inc. (NYSE:ZTS) earned “Buy” rating by Piper Jaffray on Friday, September 29.

Copper Rock Capital Partners Llc decreased Synovus Financial Corp (NYSE:SNV) stake by 31,410 shares to 571,230 valued at $26.03 million in 2017Q3. It also reduced Callon Pete Co Del (NYSE:CPE) stake by 95,284 shares and now owns 1.71 million shares. Lumentum Holdings Inc was reduced too.

Investors sentiment increased to 1.1 in Q3 2017. Its up 0.06, from 1.04 in 2017Q2. It is positive, as 41 investors sold ZTS shares while 233 reduced holdings. 62 funds opened positions while 240 raised stakes. 440.74 million shares or 0.80% less from 444.27 million shares in 2017Q2 were reported. Dana Invest Advisors stated it has 0.25% in Zoetis Inc. (NYSE:ZTS). Schroder Group stated it has 145,754 shares or 0.02% of all its holdings. Heritage Invsts Management reported 1.11% stake. Thompson Davis And holds 0.02% of its portfolio in Zoetis Inc. (NYSE:ZTS) for 192 shares. Cantab Cap Partners Limited Liability Partnership, United Kingdom-based fund reported 6,183 shares. 20.17 million were reported by State Street. Atlanta L L C has invested 0.52% of its portfolio in Zoetis Inc. (NYSE:ZTS). Waters Parkerson & Limited Liability Co reported 0.06% in Zoetis Inc. (NYSE:ZTS). Pictet Asset Ltd has invested 0.15% in Zoetis Inc. (NYSE:ZTS). Moreover, Kepos Limited Partnership has 0.09% invested in Zoetis Inc. (NYSE:ZTS) for 8,124 shares. Tokio Marine Asset Management stated it has 0.17% of its portfolio in Zoetis Inc. (NYSE:ZTS). Northern holds 0.1% or 5.84M shares in its portfolio. Boussard Gavaudan Management Llp invested in 0.07% or 23,522 shares. Picton Mahoney Asset Mgmt reported 1.75% stake. Taurus Asset Limited Company holds 0.06% or 5,927 shares.